9. January 2015

FDA Approves Roche's Blood Screening Assay for Simultaneous Detection and Identification of Three Major Viral Targets

Roche announced today that the FDA has approved the cobas® TaqScreen MPX Test, v2.0 for use in the detection and identification of HIV, HCV, and HBV in donations of human whole blood and blood components including source plasma.


Learn about testing for Influenza
What's New

22. December 2015

New Roche HBV Test expands cobas® 4800 System menu

Complete virology portfolio strengthens high medical value capabilities.


21. December 2015

Roche receives FDA approval for HIV-1 viral load test on the cobas® 6800/8800 Systems

HIV-1 test expands menu for highly automated molecular platforms that offer fastest time to results.


13. November 2015

Roche receives FDA approval for cobas® EGFR Mutation Test v2 as a companion diagnostic for non-small cell lung cancer therapies

Next-generation test using tissue samples is approved for use as a companion diagnostic with AstraZeneca’s new therapy, TAGRISSO™.


3. November 2015

Roche expands cobas 4800 System menu with HIV-1, HCV and HCV Genotyping Tests

Roche announced today the commercial availability of the cobas HIV-1, HCV and HCV Genotyping (GT) assays in countries accepting the CE mark1.


 Diagnostic and Blood Screening Tests


Roche Molecular Diagnostics (RMD) offers a uniquely broad range of diagnostic and blood screening assays based on the company's Nobel prize-winning PCR technologies.


RMD's tests and automated platforms are focused in the areas of virology, blood screening, HPV, genomics and oncology, microbiology and sexually transmitted infections. > more


Contact your local sales representative for detailed information, questions and ordering.



 Browse Our Products

 Related Links